Skip to Content
Morningstar

Danaher Corp - Stock Quote DHR

Morningstar Rating
Rating as of

Morningstar's Danaher Corp Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Danaher Benefits From Omicron Variant Surge in Q1, but Headwinds Emerging; Shares Rich

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

Narrow-moat Danaher turned in strong operating results for the first quarter, which included the omicron variant surge that helped the firm exceed our expectations and FactSet consensus. However, Danaher maintained its guidance for the year, which suggests growth will decelerate significantly, and we are maintaining our $200 fair value estimate. Shares still appear rich to us when considering the potential for a profit growth reset, as the COVID-19 pandemic likely turns endemic in the near future.

Read Full Analysis

Danaher Corp's Company Profile

Business Description

In 1984, Danaher’s founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE’s Biopharma business, now called Cytiva, which added to its life sciences segment.

Contact
2200 Pennsylvania Avenue, North West, Suite 800W
Washington, DC, 20037-1701
T +1 202 828-0850
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Aggressive Growth
Employees 80,000

Danaher Corp's Related Articles & News

Market Update

29 Stock Funds That Flip-Flopped in the Rankings

These funds moved from best to worst, or from worst to best, amid the stock market's volatility.
Katherine Lynch
Market Update

Markets Brief: Bond Yields Rise, Bank Stocks Struggle

Major banks start reporting. Delta and travel stocks rise higher. Healthcare stocks reverse gains while Nvidia and AMD extend losses.
Jakir Hossain
Fund Spy

13 Funds to Buy For Your IRA

I've got you covered from high risk to low risk.
Russel Kinnel
Commentary

This Year’s Outperforming Large-Growth Fund Managers

Few funds have been able to beat their benchmark as high-flying companies like Tesla drive benchmarks.
Katherine Lynch
Fund Spy

Are Water Funds Too Watered Down?

Climate change has underscored the need for clean drinking water. Does that make investing in water funds a compelling option?
Bobby Blue
Sustainability Matters

How Did Large-Cap Sustainable Stock Funds Perform in Q3?

Stock-pickers led the way, particularly high-conviction funds.
Leslie Norton
Market Update

U.S. Equity Market Valuation Update: Stick With Value

Value stocks struggled in July, but we continue to see this category as the best opportunity for long-term investors.
David Sekera
Fund Spy

A Terrific, Time-Tested Dividend-Growth Fund

An upcoming organizational change isn't a concern for Silver-rated T. Rowe Price Dividend Growth.
Stephen Welch
Commentary

Was Tesla Key to ESG Outperformance Last Year?

Maybe, but there were other factors at play.
Katherine Lynch
Fund Spy

This ESG Fund From Vanguard Is Off to a Good Start

The managers of the firm's first actively managed environmental, social, governance fund take a sensible, concentrated approach.
David Kathman
Commentary

Before You Sell Anything in Your 401(k), Read This

We think stocks will eventually recover from this downturn, and investors shouldn't wait on the sidelines until they do.
Karen Wallace
Premium Article

5 Stocks to Watch

These companies are all new to coverage during the past two months--plus, they earn narrow or wide Morningstar Economic Moat Ratings.
Susan Dziubinski
Investing Specialists

Ultimate Stock-Pickers' Top 10 Buys and Sells

The most compelling story on the conviction holdings list of our top managers is narrow-moat rated Apple.
The Morningstar Ultimate Stock-Pickers Team
Stock Analyst Update

Our Thesis Plays Out as GE Sells BioPharma to Danaher

We're still evaluating the deal, but we don't expect a change to GE's fair value estimate.
Joshua Aguilar
US Videos

A Fast-Growing Slice of the Healthcare Sector for Your Radar

Life science and diagnostics firms offer attractive growth and moats, but be wary of valuations.
Michael Waterhouse
Investing Specialists

Ultimate Stock-Pickers: Top 10 Buys and Sells

Wide-moat rated MasterCard replaces Bank of America on the list of top 10 conviction holdings.
The Morningstar Ultimate Stock-Pickers Team
Investing Specialists

Ultimate Stock-Pickers' Top 10 High-Conviction Picks and New-Money Buys

While overall activity for our managers decreased again, we did uncover a few ideas worth considering.
The Morningstar Ultimate Stock-Pickers Team
Investing Specialists

Ultimate Stock-Pickers' Top 10 Buys and Sells

What top managers were doing in the months leading up to the global equity market downturn.
The Morningstar Ultimate Stock-Pickers Team
Investing Specialists

Ultimate Stock-Pickers’ Top 10 High-Conviction and New-Money Purchases

Big moves were scarcer in the second quarter among these top money managers.
The Morningstar Ultimate Stock-Pickers Team
Investing Specialists

Ultimate Stock-Pickers: Top 10 Buys and Sells

Top managers continue to find opportunities for some new-money purchases, while taking full advantage of a rising stock market to book gains in shares trading above their fair value estimates.
The Morningstar Ultimate Stock-Pickers Team